RY 109
Alternative Names: AST-202; RY 109Latest Information Update: 23 Aug 2023
At a glance
- Originator Aston Science; Reyon Pharmaceutical
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants; Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer